Who was studied, and how
Three numbers in the abstract
Where each one falls
Where it lands on the map
689people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
linagliptin + LD metformin
HD metformin
No clear effect on long-term blood sugar−0.01
randomisedthe abstract, start to end
… a mean baseline of 8.0% (64 mmol/mol) by -0.99% (-11 mmol/mol) for linagliptin + LD metformin, and -0.98% (-11 mmol/mol) for HD metformin [treatment difference -0.01% (95% confidence interval …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Change in glycated hemoglobin (HbA1c) from baseline to Week 14linagliptin + LD metformin vs baseline
−0.99
Change in glycated hemoglobin (HbA1c) from baseline to Week 14HD metformin vs baseline
−0.98
Change in glycated hemoglobin (HbA1c) from baseline to Week 14linagliptin + LD metformin vs HD metformin
−0.01−0.13 to 0.12
MetforminDPP-4 inhibitorsAdverse events & safety
1 / 4